{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:45Z","timestamp":1792172385958,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:59:47Z","timestamp":1619153987000},"page":"268-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies"],"prefix":"10.1016","volume":"25","author":[{"given":"Stefano","family":"Di Bella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Enrico","family":"Maraolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Viaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luzzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Luzzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.04.001_bib0001","doi-asserted-by":"crossref","first-page":"e02446","DOI":"10.1128\/AAC.02446-17","article-title":"Avibactam pharmacokinetic\/pharmacodynamic targets","volume":"62","author":"Nichols","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0002","unstructured":"EML Secretariat on behalf of the EML Antibiotic Working Group. Application for inclusion of ceftazidime\u2013avibactam (J01DD52) as a reserve antibiotic on the WHO Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children (EMLc). https:\/\/www.who.int\/selection_medicines\/committees\/expert\/22\/applications\/s6.2_new-antibiotics-AWaRe.pdf?ua=1 [accessed 17 May 2020]."},{"key":"10.1016\/j.jgar.2021.04.001_bib0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2020-0012","article-title":"Update on the role of ceftazidime\u2013avibactam in the management of carbapenemase-producing Enterobacterales","volume":"15","author":"Dietl","year":"2020","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2021.04.001_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0005","series-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.jgar.2021.04.001_bib0006","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jgar.2019.06.009","article-title":"Use of colistin in adult patients: a cross-sectional study","volume":"20","author":"Giacobbe","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.001_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.04.001_bib0009","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime\u2013avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0010","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0011","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime\u2013avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime\u2013avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.001_bib0013","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jgar.2021.04.001_bib0014","doi-asserted-by":"crossref","first-page":"e00989","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to ceftazidime\u2013avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity","volume":"61","author":"Nelson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0015","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to ceftazidime\u2013avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime\u2013avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0017","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0018","doi-asserted-by":"crossref","first-page":"e00451","DOI":"10.1128\/AAC.00451-17","article-title":"Impaired inhibition by avibactam and resistance to the ceftazidime\u2013avibactam combination due to the D179Y substitution in the KPC-2 \u03b2-lactamase","volume":"61","author":"Compain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0019","doi-asserted-by":"crossref","first-page":"e00079","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime\u2013avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem\u2013relebactam and meropenem\u2013vaborbactam: two novel carbapenem\u2013\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.04.001_bib0021","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0022","series-title":"Emergence of resistance to ceftazidime\u2013avibactam in carbapenem-resistant Enterobacteriaceae \u201312 June 2018","year":"2018"},{"key":"10.1016\/j.jgar.2021.04.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jgar.2021.04.001_bib0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1192\/bja.2017.3","article-title":"How to carry out a literature search for a systematic review: a practical guide","volume":"24","author":"Atkinson","year":"2018","journal-title":"BJPsych Adv"},{"key":"10.1016\/j.jgar.2021.04.001_bib0025","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Ceftazidime\u2013avibactam: rationale for the clinical breakpoints, version 1.0 year 2020. http:\/\/www.eucast.org [accessed 22 April 2021]."},{"key":"10.1016\/j.jgar.2021.04.001_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.jgar.2021.04.001_bib0027","unstructured":"Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et\u00a0al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp [accessed 30 June 2020]."},{"key":"10.1016\/j.jgar.2021.04.001_bib0028","first-page":"e02097","article-title":"Emergence of ceftazidime\u2013avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0029","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime\u2013avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.19.1900256","article-title":"Emergence of ceftazidime\u2013avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018","volume":"24","author":"Raisanen","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.001_bib0031","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0032","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo","volume":"74","author":"Gottig","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0033","doi-asserted-by":"crossref","first-page":"e01551","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem\u2013vaborbactam as salvage therapy for ceftazidime\u2013avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0034","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000028","article-title":"Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime\u2013avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019","volume":"25","author":"Galani","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.001_bib0035","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.2.1900766","article-title":"Detection in two hospitals of transferable ceftazidime\u2013avibactam resistance in Klebsiella pneumoniae due to a novel VEB \u03b2-lactamase variant with a Lys234Arg substitution, Greece, 2019.","volume":"25","author":"Voulgari","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.001_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","article-title":"Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature","volume":"22","author":"Cano","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.001_bib0037","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the \u03a9 loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0038","doi-asserted-by":"crossref","first-page":"e01816","DOI":"10.1128\/AAC.01816-19","article-title":"Ceftazidime\u2013avibactam resistance associated with increased blaKPC-3 gene copy number mediated by pKpQIL plasmid derivatives in sequence type 258 Klebsiella pneumoniae","volume":"64","author":"Coppi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0039","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/jac\/dkz156","article-title":"KPC-31 expressed in a ceftazidime\/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues","volume":"74","author":"Antonelli","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0040","doi-asserted-by":"crossref","first-page":"e01111","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime\u2013avibactam and exhibiting reduced carbapenemase activity","volume":"63","author":"Mueller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.11.011","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: epidemiology and genomic characterization","volume":"26","author":"Gaibani","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.001_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.09.020","article-title":"Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime\/avibactam carrying a novel KPC variant (KPC-36)","volume":"55","author":"Gaibani","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.001_bib0043","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/IDR.S207993","article-title":"Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime\u2013avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae","volume":"12","author":"Venditti","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2021.04.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2019.03.011","article-title":"Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime\u2013avibactam","volume":"25","author":"Galani","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.001_bib0045","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime\u2013avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0046","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cmi.2020.03.013","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America","volume":"26","author":"Garc\u00eda","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.04.001_bib0047","doi-asserted-by":"crossref","first-page":"e00408","DOI":"10.1128\/mSphere.00408-18","article-title":"Analyses of a ceftazidime\u2013avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype","volume":"3","author":"Castanheira","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2021.04.001_bib0048","doi-asserted-by":"crossref","first-page":"e00955","DOI":"10.1128\/AAC.00955-19","article-title":"Patient-to-patient transmission of Klebsiella pneumoniae carbapenemase variants with reduced ceftazidime\u2013avibactam susceptibility","volume":"63","author":"Munoz-Price","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0049","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jgar.2020.04.007","article-title":"Epidemiology of carbapenemase-producing Klebsiella pneumoniae in northern Portugal: predominance of KPC-2 and OXA-48","volume":"22","author":"Lopes","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2021.04.001_bib0050","article-title":"Population structure of KPC carbapenemase-producing Klebsiella pneumoniae in a long-term acute-care rehabilitation facility: identification of a new lineage of clonal group 101, associated with local hyperendemicity","volume":"6","author":"Arena","year":"2020","journal-title":"Microb Genom"},{"key":"10.1016\/j.jgar.2021.04.001_bib0051","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13756-019-0613-4","article-title":"Molecular and phenotypic characterization of clinical isolates belonging to a KPC-2-producing strain of ST15 Klebsiella pneumoniae from a Vietnamese pediatric hospital","volume":"8","author":"Berglund","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2021.04.001_bib0052","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775","article-title":"Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016","volume":"23","author":"Galani","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jgar.2021.04.001_bib0053","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dky213","article-title":"Ceftazidime\/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic\/pharmacodynamic model","volume":"73","author":"Barber","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0054","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijantimicag.2018.01.011","article-title":"Activity of ceftazidime\u2013avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain","volume":"51","author":"Garc\u00eda-Castillo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.001_bib0055","doi-asserted-by":"crossref","first-page":"e02349","DOI":"10.1128\/AAC.02349-16","article-title":"Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States","volume":"61","author":"Satlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0056","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00107-16","article-title":"Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime\u2013avibactam and aztreonam\u2013avibactam","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0057","doi-asserted-by":"crossref","first-page":"e02431","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0058","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0059","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fmicb.2020.01365","article-title":"Reduced ceftazidime\u2013avibactam susceptibility in KPC-producing Klebsiella pneumoniae from patients without ceftazidime\u2013avibactam use history\u2014a multicenter study in China","volume":"11","author":"Cui","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.04.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime\u2013avibactam in the treatment of infections caused by KPC-producing K. pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.001_bib0061","doi-asserted-by":"crossref","first-page":"e01964","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime\u2013avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0062","doi-asserted-by":"crossref","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime\u2013avibactam for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0063","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime\u2013avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0064","doi-asserted-by":"crossref","first-page":"e02320","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime\u2013avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.001_bib0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0066","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0067","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10096-017-3010-z","article-title":"Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies","volume":"36","author":"Giacobbe","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0068","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with Gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.04.001_bib0069","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.001_bib0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/FTD.0000000000000857","article-title":"Optimization of aztreonam in combination with ceftazidime\/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study","volume":"43","author":"Cowart","year":"2021","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:16Z","timestamp":1761991096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":70,"alternative-id":["S2213716521000916"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}